FATE News and Press, Fate Therapeutics Inc. From 02/02/23

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Boston, Massachusetts--(Newsfile Corp. - January 23, 2023) - Block & Leviton announces that a class action lawsuit has been filed against Fate Therapeutics, Inc. (NASDAQ: FATE) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the fir...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

San Francisco, California--(Newsfile Corp. - January 13, 2023) - Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now . Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: FATE@hbsslaw.c...

SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2023 / Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ:FATE) investors who suffered significant losses to submit your losses now . Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: FATE@hbsslaw.com 844-916-...

SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now . Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: FATE@hbsslaw....

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Boston, Massachusetts--(Newsfile Corp. - January 6, 2023) - Block & Leviton is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) for potential securities law violations. Investors who have lost money in their Fate Therapeutics investment should contact the firm to learn more about how th...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Layoffs have been making headlines so far in 2023, even though we’re just a few days into the new year. That’s true even for gene-editing stocks. While the focus has been on tech — and understandably so &...